109 related articles for article (PubMed ID: 24050827)
1. Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Inoue Y; Saito T; Tsuruoka Y; Sato K; Nishio Y; Suzuki Y; Kato M; Isobe Y; Sakai H; Takahashi M; Miura I
Thromb Res; 2013 Oct; 132(4):493-4. PubMed ID: 24050827
[No Abstract] [Full Text] [Related]
2. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Boruah PK; Bolesta S; Shetty SM
Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
[TBL] [Abstract][Full Text] [Related]
3. Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Musolino C; Alonci A; Catena S; Rizzotti P; Russo S; Rotondo F; Allegra A
Acta Oncol; 2013 Jun; 52(5):1050-1. PubMed ID: 23113590
[No Abstract] [Full Text] [Related]
4. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
[TBL] [Abstract][Full Text] [Related]
5. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
[No Abstract] [Full Text] [Related]
6. Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
Hwang S; Woo Y; Kim M; Park HJ
Int J Dermatol; 2017 Feb; 56(2):e35-e37. PubMed ID: 27805271
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse reactions to lenalidomide.
Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
[TBL] [Abstract][Full Text] [Related]
8. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome.
Nakajima S; Watanabe H; Tohyama M; Sugita K; Iijima M; Hashimoto K; Tokura Y; Nishimura Y; Doi H; Tanioka M; Miyachi Y; Kabashima K
Arch Dermatol; 2011 Sep; 147(9):1110-2. PubMed ID: 21931056
[No Abstract] [Full Text] [Related]
9. Lenalidomide: Stevens-Johnson syndrome.
Prescrire Int; 2010 Jun; 19(107):125. PubMed ID: 20740722
[No Abstract] [Full Text] [Related]
10. The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
Fujita H; Matsukura S; Watanabe T; Komitsu N; Watanabe Y; Takahashi Y; Kambara T; Ikezawa Z; Aihara M
Br J Dermatol; 2014 Dec; 171(6):1585-8. PubMed ID: 24903194
[No Abstract] [Full Text] [Related]
11. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
[No Abstract] [Full Text] [Related]
12. Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Sakai M; Kubota T; Takaoka M; Tsukuda T; Arakawa Y; Anabuki K; Ikezoe T; Togitani K; Yokoyama A
Ann Hematol; 2015 May; 94(5):891-2. PubMed ID: 25407112
[No Abstract] [Full Text] [Related]
13. Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.
Das A; Sil A; Mishra V; Das NK
Indian J Pharmacol; 2014; 46(5):557-9. PubMed ID: 25298592
[TBL] [Abstract][Full Text] [Related]
14. Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Sakai H; Kato M; Takahashi M; Miura I
Leuk Lymphoma; 2013 Sep; 54(9):1953-8. PubMed ID: 23339448
[TBL] [Abstract][Full Text] [Related]
15. [Desensitization to lenalidomide].
Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
[No Abstract] [Full Text] [Related]
16. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
19. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
20. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
